Nano-in-Micro Dual Delivery Platform for Chronic Wound Healing Applications

Abstract

Here, we developed a combinatorial delivery platform for chronic wound healing applications. A microfluidic system was utilized to form a series of biopolymer-based microparticles with enhanced affinity to encapsulate and deliver vascular endothelial growth factor (VEGF). Presence of heparin into the structure can significantly increase the encapsulation efficiency up to 95% and lower the release rate of encapsulated VEGF. Our in vitro results demonstrated that sustained release of VEGF from microparticles can promote capillary network formation and sprouting of endothelial cells in 2D and 3D microenvironments. These engineered microparticles can also encapsulate antibiotic-loaded nanoparticles to offer a dual delivery system able to fight bacterial infection while promoting angiogenesis. We believe this highly tunable drug delivery platform can be used alone or in combination with other wound care products to improve the wound healing process and promote tissue regeneration.

Antibacterial and Osteoinductive Implant Surface Using Layer-by-Layer Assembly

“…Gentamicin as a model antibiotic drug was mixed with PLL (1:1 mass ratio) and used during the LbL coating process. Detailed information on gentamicin loading and release procedure are in Appendix (Zarubova et al 2020). The release was evaluated for 3 initial loading levels of 5-, 10-, and 75-µg gentamicin per implant.…”

Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations

“…89 Prolonged inflammation caused by low concentrations of GFs can hinder proper angiogenesis and delay the wound healing process, rendering wounds more vulnerable to bacterial infections. Zarubova et al 90 employed microencapsulation techniques to create VEGF-loaded microparticles (MP-VEGF), using a combination of alginate and heparin. The inclusion of heparin enhanced the affinity of the microparticles for the GF.…”

Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of In Vitro and In Vivo Studies

“…The low concentration of growth factors is one of the causes of inflammatory process prolongation, which causes insufficient angiogenesis and delays healing of wounds that become more susceptible to bacterial infections. Thinking about it, Zarubova et al [ 86 ] microencapsulated the vascular endothelial growth factor A (VEGF) in a conjugation of alginate-heparin (MP-VEGF), as heparin increases the bioaffinity for the growth factor, and co-encapsulated gentamycin-loaded nanoparticles in the resulting microparticles. In a 3D microenvironment used to test the impact of MP-VEGF on angiogenesis, more endothelial sprouts with larger size were observed in MP-VEGF samples than in the free VEFG ones.…”